Induced pluripotent stem cell technology: Toward the future of cardiac arrhythmias.

[1]  Stefano Severi,et al.  Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes , 2017, Cardiovascular research.

[2]  D. Sinnecker,et al.  Perspectives and Challenges of Pluripotent Stem Cells in Cardiac Arrhythmia Research , 2017, Current Cardiology Reports.

[3]  Response by Crotti et al to Letter Regarding Article, "Genetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3' Untranslated Region of KCNQ1?" , 2016, Circulation. Cardiovascular genetics.

[4]  Brian J. Stevenson,et al.  TECRL, a new life‐threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT , 2016, EMBO molecular medicine.

[5]  T. Meitinger,et al.  Genetic Modifiers for the Long-QT Syndrome: How Important Is the Role of Variants in the 3' Untranslated Region of KCNQ1? , 2016, Circulation. Cardiovascular genetics.

[6]  Adriaan P IJzerman,et al.  A new hERG allosteric modulator rescues genetic and drug‐induced long‐QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells , 2016, EMBO molecular medicine.

[7]  S. Yamanaka,et al.  A decade of transcription factor-mediated reprogramming to pluripotency , 2016, Nature Reviews Molecular Cell Biology.

[8]  Robert Passier,et al.  Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology , 2015, EMBO molecular medicine.

[9]  Simona Casini,et al.  Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem? , 2015, Stem cells and development.

[10]  Milena Bellin,et al.  Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: Disease mechanisms and pharmacological rescue , 2014, Proceedings of the National Academy of Sciences.

[11]  Praveen Shukla,et al.  Chemically defined generation of human cardiomyocytes , 2014, Nature Methods.

[12]  K. Morgan,et al.  Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes , 2013, European heart journal.

[13]  A. Mehta,et al.  Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes. , 2014, Cardiovascular research.

[14]  Teng Hong Tan,et al.  Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. , 2013, International journal of cardiology.

[15]  Lia Crotti,et al.  Long-QT syndrome: from genetics to management. , 2012, Circulation. Arrhythmia and electrophysiology.

[16]  Jonathan A. Bernstein,et al.  Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome , 2011, Nature.

[17]  Lior Gepstein,et al.  Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.

[18]  Karl-Ludwig Laugwitz,et al.  Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, The New England journal of medicine.

[19]  LimorZwi,et al.  Cardiomyocyte Differentiation of Human Induced Pluripotent Stem Cells , 2009 .

[20]  Sean P. Palecek,et al.  Functional Cardiomyocytes Derived From Human Induced Pluripotent Stem Cells , 2009, Circulation research.

[21]  Ronald Wilders,et al.  Dynamic clamp: a powerful tool in cardiac electrophysiology , 2006, The Journal of physiology.

[22]  Carlo Napolitano,et al.  Erratum: Long QT syndrome patients with mutations on the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate: Implications for gene-specific therapy (Circulation (1995) 92 (3381-3386)) , 1996 .

[23]  S. Priori,et al.  Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. , 1995, Circulation.